Skip to content

Site logo

Main menu
  • Company
    • Who we are
    • What we do
    • Stories
    • History
    • Sustainability
      • Sustainability overview
      • Philanthropy
      • Merck Medical Outreach Program
      • Impact Venture Fund
      • Transparency disclosures
      • Sustainability resources
    • Leadership
      • Leadership overview
      • Board of directors
      • Executive team
    • Culture & values
      • Culture & values overview
      • Code of conduct, ethics & compliance
    • Diversity and inclusion
    • Policies & positions
    • Suppliers
      • Suppliers overview
      • Supplier registration
      • Supplier help for Ariba
  • Research
    • Research overview
    • Areas of focus
      • Oncology
      • Vaccines
      • Infectious diseases
      • Cardio-metabolic disorders
      • Immunology
      • Neuroscience
      • Ophthalmology
    • Areas of innovation
      • Data science and artificial intelligence 
      • Green and sustainable science
    • Pipeline
    • Business development and licensing (BD&L)
    • Clinical trials
      • Clinical trials overview
      • Find a trial
      • Diversity in clinical trials
    • R&D locations
    • How we invent
    • Meet our scientists
    • Publications
  • Products
    • Products list
    • Safety data sheets
    • Product patents
    • Merck authorized distributors
  • Patients
    • Patients overview
    • Patient support programs
    • Play an active role in your health care
  • Investors
    • Investors overview
    • Events & presentations
    • Financial information
      • Financial information overview
      • SEC filings
    • Stock information
    • Investor resources
  • Media
    • Media overview
    • News releases
    • Company statements
    • Media library & contacts
    • Company fact sheet
  • Careers
Scientist reviewing test tubes

Who we are

Learn more
Contact us

What can we help you find?

Search for:

Antibiotics

View all stories
article thumbnail

How you can help slow the threat of antimicrobial resistance

The growing burden of AMR is threatening the return to a world without effective antibiotics

October 30, 2023

Connect with us on social

social icon social icon social icon social icon social icon
  • MerckHelps
    Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients.
  • Merck Access Program
    Information about insurance coverage and financial assistance options for eligible patients.
  • Clinical trials
    Learn about our clinical trials and find available studies.
  • Merck Manuals
    Medical information source covering thousands of topics in all fields of medicine.
  • Impact Report
    Reporting on our commitment to operating responsibly to benefit society.
  • Merck for Mothers
    An initiative to create a world where no woman has to die giving life.
  • Merck Animal Health
    The global animal health business unit of Merck.
  • Health Plan - Transparency in Coverage
    In compliance with the Consolidated Appropriations Act, learn more about our health plan’s pricing information.
  • Contact Us
    If you have a question or need more information about us, find out who you should contact.
  • Forward-looking statement
  • Cookie policy
  • Privacy
  • Transparency disclosure
  • Terms of use
  • Accessibility
  • Sitemap
  • Consumer Health Data Privacy Policy
  • Your Privacy Choices
Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. | This site is intended only for residents of the United States and Canada.
Accessibility icon View Privacy Shield Verification Status View APEC CBPR Privacy Certification Status

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

This website of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.


Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
No Duty to Update
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

You are leaving Merck.com

Continue

Welcome to Merck.com

By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Rahway, NJ USA.

Continue